Analysis and comparison of the prognosis of combined and pure small cell lung cancer

Chinese Journal of Clinical Oncology

Volumn 41, Issue 11, 2014, Pages 720-723

  Qin, Aiying ^a   Qian, Yaqin ^a   Cao, Wenfeng ^a   Cao, Shui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Combined small cell lung cancer; Prognosis analysis; Surgery

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PURE LUNG SMALL CELL CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; UNIVARIATE ANALYSIS;

EID: 84903777001     PISSN: 10008179     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.20140175     Document Type: Article

References (15)

1. Travis WD. Pathology and genetics of tumours of the lung, pleura, thymus and heart[M]. Lyon: IARC Press, 2004:344.
2. Mangum MD, Greco FA, Hainsworth JD, et al. Combined small-cell and non-small cell lung caancer[J]. J Clin Oncol, 1989, 7(5):607-612. (Pubitemid 19126796)
3. Wagner PL, Kitabayashi N, Chen YT, et al. Combined small cell lung carcinomas: genotypic and immunophenotypic analysis of the separate morphologic components[J]. Am J Clin Pathol, 2009, 131(3):376-382.
4. Fukui T, Tsuta K, Furuta K, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung[J]. Cancer sci, 2007, 98(11):1714-1719. (Pubitemid 47487906)
5. Lv X, Sun LN, Zhan ZL, et al. Clinicopathological Characteristics and Prognosis of Combined Small Cell Lung Cancer[J]. Chin J Clin Oncol, 2011, 38(13):769-772.
6. Babakoohi S, Fu P, Yang M, et al. Combined SCLC clinical and pathologic characteristics[J]. Clin Lung Cancer, 2013, 14(2):113-119.
7. Hirsch FR, Osterlind K, Hansen HH. The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients[J]. Cancer, 1983, 52(11):2144-2150. (Pubitemid 14232260)
8. Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets[J]. Semin Oncol, 2014, 41(1):133-142.
9. de Antonio DG, Alfageme F, Gamez P, et al. Results of surgery in small cell carcinoma of the lung[J]. Lung Cancer, 2006, 52(3):299-304. (Pubitemid 44275318)
10. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours[J]. Surg Oncol, 2014, 23(1):31-39.
11. Yao Y, Yuan D, Liu H, et al. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy[J]. Cancer Immunol Immunother, 2013, 62(3):471-479.
12. Suzuki K, Kachala SS, Kadota K, et al. Prognostic immune markers in non-small cell lung cancer[J]. Clin Cancer Res, 2011, 17(16):5247-5256.
13. Gong L, Cai Y, Zhou X, et al. Activated platelets interact with lung cancer cells through Pselectin glycoprotein ligand-1[J]. Pathol Oncol Res, 2012, 18(4):989-996.
14. Hoos A, Protsyuk D, Borsig L. Metastatic growth progression caused by PSGL-1-mediated recruitment of monocytes to metastatic sites[J]. Cancer Res, 2014, 74(3):695-704.
15. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer[J]. Br J Cancer, 2000, 82(8):1427-1432. (Pubitemid 30175909)